Last reviewed · How we verify

NCT04374188

Efficacy of Ciprofloxacin Therapy in Avoidance of Sepsis in Patient Undergoing Percutanous Nephrolithotomy

Status unknown NA Last updated 3 March 2021
What this trial tests

NA trial testing Ciprofloxacin in Nephrolithiasis in 200 participants. Status unknown.

Timeline
1 September 2019
Primary endpoint
1 September 2021
1 March 2022

Quick facts

Lead sponsorDiaa Eldin Taha Ramadan Mohamed
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment200
Start date1 September 2019
Primary completion1 September 2021
Estimated completion1 March 2022
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Diaa Eldin Taha Ramadan Mohamed

Who can join

18 and older, any sex, with Nephrolithiasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Efficacy of ciprofloxacin therapy in avoidance of sepsis in patient undergoing percutanous nephrolithotomy. A randomized controlled trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ciprofloxacin

Trials testing the same drug.

Other recruiting trials for Nephrolithiasis

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04374188.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing